Merger & Acquisition

WebMD considers sale or merger

WebMD considers sale or merger

By

Drugmakers are becoming much more cautious with their budgets, WebMD executives said.

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Wednesday, August 3, 2016

Five things for pharma marketers to know: Wednesday, August 3, 2016

By

Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info

Five things for pharma marketers to know: Thursday, April 7, 2016

Five things for pharma marketers to know: Thursday, April 7, 2016

By

Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's

WPP acquires CMI, retains minority stake in Compas

WPP acquires CMI, retains minority stake in Compas

By

WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.

Sudler & Hennessey acquires West Coast digital marketing firm

Sudler & Hennessey acquires West Coast digital marketing firm

By

Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.

Is This the End of Agency Diversification?

Is This the End of Agency Diversification?

By

DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.

Five things for pharma marketers to know: Wednesday, October 14, 2015

Five things for pharma marketers to know: Wednesday, October 14, 2015

By

J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters